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METHOD OF TREATING PARKINSON’S
DISEASE IN HUMANS BY
CONVECTION-ENHANCED INFUSION OF
GLIAL CELL-LINE DERIVED
NEUROTROPHIC FACTOR TO THE
PUTAMEN

and Neurochemical Effects of Intranigral GDNF Admini stra
tion on Aged Fischer 344 Rats. J. Pharm. Exp. Ther., 282:
760-768 (1997); Hou, J. G. G., et al., Glial Cell line-Derived

Neurotrophic Factor Exerts Neurotrophic Effects on Dopam
inergic Neurons In Vitro and Promotes Their Survival And

Regrowth After Damage by 1-Methyl-4-Phenylpyridinium.
J. Neurochem., 66:74-82 (1996); Kordower, J. H., et al.,

Clinicopathological Findings Following Intraventricular

This application was ?led as a US. National Phase Appli

Glial-Derived Neurotrophic Factor Treatment in a Patient

cation pursuant to 35 U.S.C. §371 of International Applica
tion No. PCT/US2005/034347 which was ?led Sep. 22, 2005,
which is a continuation-in-part of US. application Ser. No.
10/784,547 which was ?led Feb. 23, 2004, which in turn
claims bene?t under 35 U.S.C. §119 ofU.S. Application Ser.
No. 60/499,317 which was ?led Feb. 24, 2003. The entire
disclosure of each of the foregoing applications is incorpo
rated herein by reference in its entirety.
FIELD OF THE INVENTION

The present invention relates generally to the ?eld of neu

20

robiology. More particularly, it concerns methods for treating
Parkinson’ s disease in humans and related methods of restor

ing atrophic dopaminergic neurons and protecting dopamin
ergic neurons at risk of degeneration are also described.

This application contains, as a separate part of disclosure,

25

with Parkinson’s Disease. Ann Neurol., 46(3):419-424
(1999); Kordower, J. H., et al., Neurodegeneration Prevented
by Lentiviral Vector Delivery of GDNF in Primate Models of
Parkinson’s Disease. Science, 290:767-773 (2000); Pal?, S.,
et al., Lentivirally Delivered Glial Cell Line-derived Neu
rotrophic Factor Increases the Number of Striatal Dopamin
ergic Neurons in Primate Models of Nigrostriatal Degenera
tion. J. Neurosci., 22:4942-4954 (2002); Tomac, A., et al.,
Protection and Repair of the Ni gro striatal Dopaminergic Sys
tem by GDNF In Vivo, Nature, 373:335-339 (1995)). How
ever, initial clinical trials involving ventricular delivery of
GDNF showed no statistically signi?cant differentiation of
the placebo and active treatment groups (Nutt, J. G., et al.,
ICV GDNF Study Group. Implanted intracerebroventricular.
Glial Cell Line-derived Neurotrophic Factor. Randomized,
Double-Blind Trial of Glial Cell Line-Derived Neurotrophic

a Sequence Listing in computer-readable form (?lename:

Factor (GDNF) in PD, Neurology, 60: 69-73 (2003)), perhaps

40551A_SeqListing_ST25.txt; crated Apr. 7, 2011; 7,743

because insu?icient amounts of GDNF reached critical target

bytesiASCII text ?le) which is incorporated by reference in
its entirety.

Aging Rhesus Monkeys: Distribution and Dopaminergic

sites from the CSF (Ai, Y., et al., Intraputamenal Infusion in

BACKGROUND OF THE INVENTION

Effects. J. Comp Neurol. 461: 250-26125 (2003); Kordower,
J. H., et al., (2000)).

Current treatments for Parkinson’s disease (PD) become
increasingly less ef?cacious as the disease progresses, and do

Consequently, there continues to exist a long-felt need for
effective methods for the treatment and prevention of PD in
humans. Accordingly, it is an object of the present invention

30

little to slow the underlying pathophysiological changes in

35

the nigrostriatal dopaminergic system (Rascol, O., et al.,
Limitations of Current Parkinson’s Disease Therapy, Ann.

Neurol., 53 Suppl 3:S3-12 (2003); Romell, 1., et al., Rationale
for Current Therapies in Parkinson’s Disease, Expert Opin.

Pharmacother., 4:1747-1761 (2003)). Neurotrophic factors,
proteins which activate cell signaling pathways regulating
neuronal survival, differentiation, growth and regeneration,
offer promising therapy for treating dopamine neurons in PD,

skilled artisan from this disclosure.
40

SUMMARY OF THE INVENTION
A ?rst aspect of the present invention concerns a method of

treating Parkinson’s disease in a human comprising admin

istering a pharmaceutical composition comprising a pharma

but are dif?cult to administer clinically as they do not pass

through the blood brain barrier (Beck, K. D., et al., Mesen
cephalic Dopaminergic Neurons Protected by GDNF from

to provide methods of treating PD in humans comprising
intraputaminal convection-enhanced infusion of GDNF. This
and other such objectives will be readily apparent to the

Axotomy-Induced Degeneration in the Adult Brain, Nature,

ceutically effective dose of a glial cell line-derived neu
rotrophic factor (GDNF) protein product to one or both
putamen of a human PD patient in need thereof. The GDNF

373:339-3416 (1995); Bjorklund, A., et al., Towards a Neu
roprotective Gene Therapy for Parkinson’s Disease: Use Of

protein product includes, without limitation, a pharmaceuti
cally effective dose of r-metHuGDNF (a dimeric protein hav

Adenovirus, AAV and Lentivirus Vectors for Gene Transfer of
GDNF to the Nigrostriatal System in the Rat Parkinson

Model, Brain Res., 886:82-98 (2000)). Glial cell line-derived
neurotrophic factor (GDNF) is a trophic factor shown to
dramatically protect and enhance the function of dopamine
neurons in vitro and in vivo in rodents and monkeys (Beck, K.

45
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the surprising discovery that convection-enhanced infusion
of r-metHuGDNF to one or both putamen of a PD patient by
means of at least one implantable pump and one or more
55

impressive re-innervation and/or restoration of dopamine
stores in previously dopamine de?cient neurons in human
patients af?icted with PD.

Striatal GDNF Infusion Promotes Structural and Functional
60

The methods of the present invention are contemplated to
restore neural cell function in a patient having Parkinson’s
disease. Furthermore, the methods described herein are use

ful in repairing neural pathways damaged by Parkinson’s

Aged Rhesus Monkeys, J. Neurosci., 23:1974-1980 (2003);
Hebert M. A., et al., Functional Effects of GDNF in Normal
Rat Striatum: Presynaptic Studies Using In Vivo Electro
chemistry and Microdialysis. J. Pharm. Exp. Ther., 279:1 181 1190 (1996); Hebert M. A. and Gerhardt, G. A., Behavioral

indwelling catheters results in dramatic anti-parkinsonian
and anti-dyskinetic effects which are further associated with

D., et al., (1995); Bjorklund,A., et al., (2000); Gash, D. M., et
al., Functional Recovery in Parkinsonian Monkeys Treated
with GDNF, Nature, 380:252-255 (1996); Grondin, R., et al.,
Recovery in Advanced Parkinsonian Monkeys. Brain, 125:
2191-2201 (2002); Grondin, R., et al., GDNF Increases
Stimulus-evoked Dopamine Release and Motor Speed in

ing an the amino acid sequence shown below in Table 1) or
variants and/or derivatives thereof. The invention is based on

65

disease in humans. Speci?cally, the methods described herein
are capable of stimulating nerve regeneration, including re

innervation of damaged human brain tissue by dopaminergic
neurons. In a related aspectthere is provided a method of

US 8,946,152 B2
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increasing the function of dopaminergic neurons that com

map (dark greyiputamen; light grenglobus pallidus) from

prises convection-enhanced infusion of a pharmaceutically

the ten subjects. LiPatient Left. Scale Bar (top right)—10

effective dose of r-metHuGDNF to one or both putamen of a

mm.

human patient in need thereof using at least one implantable
pump and at least one catheter.
The present invention also concerns the use of a pharma

FIGS. 2(a) and 2(b) depicts patient assessments made
using validated quality of life questionnaires: the 39-item
Parkinson’s Disease Questionnaire (PDQ 39; FIG. 2(a)) and

ceutically effective amount of GDNF and at least one phar

the 36-item Medical Outcomes Study short form health sur

maceutically acceptable vehicle, excipient, or diluent in the
preparation of a pharmaceutical composition for increasing
the function of dopaminergic neurons, wherein the composi

vey (SF-36; FIG. 2(b)) before surgery and after 3, 6, 12, 18,
and 24 months of convection-enhanced infusion of r-metH
uGDNF to the putamen, either unilaterally or bilaterally,
using one or more single-port catheters.

tion is administeredto one or both putamen of a human in need

FIGS. 3(a) and 3(b) depicts the UPDRS scores for patients
at 0, 3, 6, 12, 18, and 24 months of convection-enhanced
infusion of r-metHuGDNF to the putamen, either unilaterally

thereof via convection-enhanced infusion using at least one
implantable pump and at least one catheter.

Additionally provided are methods of treating cognitive

or bilaterally using one or more single-port catheters.

disorders in humans that comprise administeration of a phar
maceutically effective dose of r-metHuGDNF to one or both

DETAILED DESCRIPTION OF CERTAIN
PREFERRED EMBODIMENTS

putamen of a human patient in need thereof via convection
enhanced infusion using at least one implantable pump and at
least one catheter.

20

Another aspect of the present invention includes methods
of treating PD or cognitive disorders comprising the admin
isteration of a pharmaceutically effective dose of r-metH
uGDNF to one or both putamen of a human in need thereof

via convection-enhanced infusion using at least one implant
able pump and at least one catheter and assessing dopamin

25

ergic function in the brain of said human pre-operatively, and,
optionally, assessing dopaminergic function in the brain of
said human periodically post-operatively.
The methods disclosed herein may also provide a prophy
lactic function in humans. More speci?cally, one embodi
ment of the present invention includes a method of preventing
PD in a human comprising administration of r-metHuGDNF

30

human PD patient using at least one implantable pump and at
least one indwelling catheter results in surprisingly dramatic
anti-parkinsonian and anti-dyskinetic effects which are asso
ciated with impressive re-innervation and restoration of
dopamine stores in previously dopamine de?cient neurons.
Macromolecules like GDNF diffuse slowly in brain paren

chyma and usually over only short distances (Bobo, R. H., et
al., Convection-Enhanced Delivery of Macromolecules in the
Brain. Proc. Nat. Acad. Sci USA, 91:2076-2080 (1994)).
Convection enhanced delivery (CED) to the brain uses bulk
?ow in the extracellular space that results from a pressure

gradient to signi?cantly enhance tissue penetration and dis
tribute macromolecules over larger volumes in relatively

to one or both putamen of a human via convection-enhanced

infusion using at least one implantable pump and at least one

This invention is based on the discovery that convection
enhanced infusion of GDNF to one or both putamen of a

35

homogenous concentrations and largely independent of
molecular weight. This is in stark contrast to diffusion that is
dependent on establishing a concentration gradient and

catheter. Another embodiment of the present invention

includes methods of preserving dopaminergic neural cell
function in a human having, or at risk of having, a neurode

depends heavily on molecular weight (Bobo, et al., (1994);

generative disorder comprising administration of r-metH

US. Pat. Nos. 5,720,720, 6,093,802 and 6,184,200 (the US.
patents are hereby incorporated by reference in their
entirety); Chen, M. Y., et al., Variables Affecting Convection

uGDNF to one or both putamen of a human via convection

40

enhanced infusion using at least one implantable pump and at
least one catheter. The neurodegenerative disorder may be

Enhanced Delivery to the Striatum: a Systematic Examina
tion of Rate of Infusion, Cannula Size, Infusate Concentra

Parkinson’s disease or multiple system atrophy (MSA).
According to the invention, r-metHuGDNF administered via
convection-enhanced infusion to the human putamen is con

45

templated to preserve the integrity of the nigrostriatal path
way in the human brain. Prophylactically administering

Distribution of the Glial-Derived Neurotrophic Factor

(GDNF) Ligand Family in Rat Striatum and Enhances the

GDNF via convection-enhanced infusion of r-metHuGDNF
in accordance with the invention is contemplated as a method

of preventing or treating degeneration of the nigrostriatal
pathway or loss of functional dopaminergic activity associ
ated with a neurodegenerative disorder. The neurodegenera

tion, and Tissue-Cannula Sealing Time, J. Neurosurg.,
90:315-20 (1999); Hamilton, J. F., et al., Heparin Coinfusion
During Convection-Enhanced Delivery (CED) Increases the

Pharmacological Activity of Neurturin, Exp. Neurol., 168:
50

155-61 (2001); Nguyen, T. T., et al., Convective Distribution
of Macromolecules in the Primate Brain Demonstrated Using

Computerized Tomography and Magnetic Resonance Imag
ing, J. Neurosurg., 98:584-90 (2003)). In a recent study in

tive disorder prevented or treated includes Parkinson’s dis

nonhuman primates (Gash, et al., unpublished data), GDNF

ease and MSA.

55 was seen to have an average area of distribution of3118 mm2

when delivered with a single port catheter (1 mm in diameter
with a 0.25 mm diameter port at the tip; Medtronic model
8770IP1A) and 119116 mm2 with a multiport catheter (1 mm
in diameter with 24 ports, each 0.075 mm in diameter;

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1(a) and 1(b) illustrate the placement of multiport
infusion catheters (represented by white circles except patient
6, represented by a black circle for clarity). Images were
normalized to the Talirach atlas in Analyze version 5.0, and
the catheter locations mapped to a single axial slice level (+4
mm). The target for multiport catheter placement was the
mid-dorsal putamen. Numbers indexing each location repre

60

sent the corresponding patient designation. The reference

65

anatomic underlay is the Talairach-normalized average

T1-weighted image with superimposed lenticular nucleus

Medtronic model 877OIP24A) using the same pump delivery
parameters. This ?nding is consistent with other studies that
show convection-enhanced infusion distributes large mol
ecules far more extensively at a relatively homogenous con

centration as compared to diffusion alone (Lieberman, D. M.,
et al., Convection-Enhanced Distribution of Large Molecules

in Gray Matter During Interstitial Drug Infusion, J. Neuro
surg., 82:1021-1029 (1995)).
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One aspect of the present invention provides methods of
treating or preventing neurodegenerative disorders in a
human that comprise administering a pharmaceutical com

experience aphthous mouth ulcers and only two reported mild
Lhennitte’s syndrome. Bilateral effects were observed in all

ten subjects. These bilateral improvements associated with

position comprising a pharmaceutically effective amount of a
GDNF protein product and at least one pharmaceutically
acceptable vehicle, excipient, or diluent to one or both puta

unilateral GDNF treatment as disclosed herein support a

facilitatory effect of improved function in the ipsilateral puta
men on bilateral motor pathways. Furthermore, the apparent
bilateral effects from unilateral administration of GDNF are

men of a human in need thereof via convection-enhanced
infusion using at least one implantable pump and at least one

surprising and unexpected in that they are not consistent with
the known dopaminergic circuitry of the basal ganglia, but are
consistent with crossed glutamatergic projections from the
motor cortex (Barbeito, L., et al., Activation of the Bilateral

catheter. The neurodegenerative disorder may be Parkinson’ s
disease or MSA.

In another embodiment of the present invention, in con
junction with the above and below embodiments, at least one

Corticostriatal Glutamatergic Projection by Infusion of

catheter is a multiport catheter. Additionally (or alterna
tively), the infusion may be pulsed.

GABA into Thalamic Motor Nuclei in the Cat: an In Vivo

Release Study, Neuroscience, 28:365-374 (1989); Glowin
ski, 1., et al., Role of the Thalamus in the Bilateral Regulation
of Dopaminergic and GABAergic Neurons in the Basal Gan

In another embodiment of the present invention, in con
junction with the above and below embodiments, at least one
catheter may be a single-port catheter from about 1 mm in
diameter to about 0.5 mm in diameter and wherein the port is

glia. Ciba Found Symp. 107:150-163 (1984)).

method of treating Parkinson’ s disease in a human that com

Accordingly, effective methods of treating or preventing
the pathological hallmarks of Parkinson’s disease in humans
as well as the devastating symptoms of PD are provided by the
present invention.
The section headings used herein are for organizational

prises administering a pharmaceutical composition compris

purposes only and are not to be construed as limiting the

at its distal end. Additionally (or alternatively), the infusion
may be pulsed.

20

Another embodiment of the present invention provides a

subject matter described.

ing a pharmaceutically effective amount of a GDNF protein

product and at least one pharmaceutically acceptable vehicle,

25

In the preceding description and the experimental disclo
sure which follows, the following abbreviations apply:

excipient, or diluent to one or both putamen of a human in

need thereof via convection-enhanced infusion of the phar
maceutical composition using at least one implantable pump

6-OHDA 6-hydroxydopamine

and at least one catheter with a single port at its distal end.

Another embodiment of the present invention provides a

Abbreviations

30

method of treating Parkinson’ s disease in a human that com

ALS amyotrophic lateral sclerosis
ASA acute systemic anaphylaxis
AUC area under the concentration vs time curve

prises administering a pharmaceutical composition compris

CAPIT Core Assessment Program for Intracerebral Trans

plantations

ing a pharmaceutically effective amount of a GDNF protein

product and at least one pharmaceutically acceptable vehicle,

CAPS 3-(cyclohexylamino)-l-propanesulfonic acid

excipient, or diluent to one or both putamen of a human in 35

CHO Chinese hamster ovary
CI continuous infusion

need thereof via convection-enhanced infusion of the phar
maceutical composition using at least one implantable pump

CSF cerebrospinal ?uid

CT computed tomography
DA dopamine, dopaminergic

and at least one catheter with a single port at its distal end and

wherein the infusion of the composition is pulsed.
The methods of the present invention may comprise con

40

DOPAC 3,4-dih:ydroxyphenylacetic acid

tinuous and/ or pulsed delivery of GDNF through one or more

E. coli Escherichia coli

catheters with a diameter of about 1 mm to about 0.5 mm and

FCA Freund’s Complete Adjuvant
GDNF glial cell line-derived neurotrophic factor

having a single port at its distal end to promote convection
enhanced distribution of GDNF which allows local tissue
concentrations of GDNF to reach threshold levels. In some

GLP Good Laboratory Practice
45

HVA homovanillic acid
ICV intracerebroventricular
IM intramuscular

embodiments of the invention, the method comprises con
tinuous and/ or pulsed delivery of GDNF utiliZing one or more
catheters with a diameter of about 0.8 mm to about 0.6 mm

and having a single port at its distal end to promote convection
enhanced distribution of GDNF which allows local tissue
concentrations of GDNF to reach threshold levels. In other
embodiments of the invention, the method comprises con
tinuous and/ or pulsed delivery of GDNF utiliZing one or more
catheters with a diameter of about 0.6 mm and having a single
port at its distal end to promote convection enhanced distri
bution of GDNF which allows local tissue concentrations of
GDNF to reach threshold levels.

ISN intranigral
50

IT intrathecal
IV intravenous

L-dopa 3,4-dihydroxyphenylalanine (levodopa)
r-metHuGDNF recombinant-methionyl human GDNF

MPTP 1 -methyl-4-phenyl- l ,2,3 ,6-tetrahydropyridine
55

PD Parkinson’s disease

PET positron-emission tomography
pmn progressive motor neuropathy
Ret receptor tyrosine kinase
r-metHuGDNF recombinant-methionyl human GDNF

Unilateral delivery of GDNF by a pulsed ?ow sequence
administered contralaterally to the most affected side using a

multi-port catheter resulted in motor improvement bilaterally
comparable to improvement seen for bilateral putamenal

HPLC high-performance liquid chromatography

60

SC subcutaneous

SDS-PAGE sodium dodecylsulfate-polyacrylamide gel

electrophoresis

GDNF continuous using a 0.6 mm diameter single port cath

eter (Gill, et al., (2003)). With both approaches, the total

SEM standard error of the mean

UPDRS scores improved in OFF and ON after 6 months of
GDNF treatment. Timed motor tests also improved, with
improvements seen in both ON and OFF. Patients adminis
tered GDNF contralaterally to the most affected side, did not

TGF transforming growth factor
TH tyrosine hydroxylase

65

TH+ tyrosine hydroxylase positive
UPDRS Uni?ed Parkinson’s Disease Rating Scale
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De?nitions
Unless otherwise noted, technical terms are used according
to conventional usage. As utilized in accordance with the
present disclosure, the following terms shall be understood to

de?cit, dopaminergic neuron de?cit, dopaminergic neuron

lesions, hypo-dopaminergic innervation, dopamine synthesis
incapacity, dopamine storage incapacity, dopamine transport

have the following meanings:

dysfunction can be evidenced by analyzing factors including,

As used herein, the term “catheter” refers to any tubular
medical device for insertion-into a cavity, tissue, organ, or any

but not limited to, the following: 1) the number of TH express

substructure thereof of a living mammal to permit injection of
a therapeutic agent. As particularly used here, a catheter is

metabolite levels 4) dopamine uptake, 5) dopamine transport,
6) neuronal dopamine uptake, 7) dopamine transporter bind

used to deliver r-metHuGDNF to the brain or substructures

ing, 8) quantal size of terminal dopamine release, 9) rate of
dopamine turnover, 10) TH+ cell count, 11) TH+ innervation
density and 12) TH+ ?ber density.
The phrase “target site”, or a grammatical version thereof,

incapacity, or dopamine uptake incapacity. Dopaminergic
ing neurons 2) size of dopamine neuronal cells 3) dopamine

thereof such as the putamen. An “indwelling” catheter is one

that is implanted and left in place for protracted periods, such
as ?fteen minutes or longer.

As used herein, the phrase “catheter system” refers to the

refers to the site for intended delivery of a substance, such as

combination of at least one catheter and at least one accessory

a drug. In particular embodiments of the present invention, a
preferred target site is an area of dopaminergic degeneration
or dopaminergic dysfunction within the brain of a human
a?licted with Parkinson’ s disease. More preferably, the target

device including, but not limited to, an anchor, stylet, guide
tube, guide wire or a combination thereof.
“Continuous delivery” or “chronic infusion” are inter
changeable and are intended to mean delivery of a substance
over a period of time such that the procedure is distinguished

site includes one or more site in the substantia nigra, globus
20

from “bolus” delivery. Continuous delivery generally
involves the delivery of a substance over a period of time
without interruption. The rate of delivery need not be con

stant, and may be pulsed, and the period of delivery need not
be very long, i.e., the period of constant delivery may be over

pallidus, caudate nucleus, and putamen. Even more prefer
ably, the target site includes the central area of the putamen.
Even more preferably, the target site includesthe posterior
area of the putamen. Mo st preferably, the target site includes
the postero-dorsal area of the putamen. Furthermore, a par

25

a period of maybe half an hour or an hour or a few hours, but

ticular target site may be targeted unilaterally or bilaterally
with respect to the hemispheres of the brain.

may also be over a period of days, weeks, months, or even

“Proximal end” is a relative term, and generally refers to

years. A pulse consists of periodic increases in the ?ow rate
for intervals ranging from seconds to minutes, to hours,
which, as used herein, enchances convection enhanced deliv
ery of the drug into brain tissue.
“Admixing” as used herein denotes the addition of an
excipient to a polypeptide of interest, such as by mixing of dry
reagents or mixing of a dry reagent with a reagent in solution
or suspension, or mixing of aqueous formulations of reagents.
“Excipient” as used herein denotes a non-therapeutic agent
added to a pharmaceutical composition to provide a desired
consistency or stabilizing effect.
“Implanted” means placed within the body, and main

the end of a device, such as a catheter that is nearest to the

tained at that location for some extended period of time. As

operator (i.e., the surgeon) and is furthest away from the
30

35

treatment site. In the present invention a catheter has a proxi
mal end that may be communicably attached to an access port
or drug delivery apparatus, such as a pump, or reservoir.

“Tyrosine hydroxylase-positive” or “TH+” is intended to
refer to the presence of tyrosine hydroxylase in a referenced
nervous tissue as indicated by the results from any technique
known in the art as a means to detect and/or measure tyrosine

hydroxyl ase, tyrosine hydroxylase encoding mRNA, or

tyrosine hydroxylase activity.
40

“Distal end” is a relative term and generally refers to the
end of a device, such as a catheter, that is furthest away from

used herein it is intended that the period of time during which

the operator (i.e., the surgeon) and is closest to the treatment

the implanted object is maintained in place will be, in general,
considerably greater than that customarily required to intro

site. In the present invention the distal end of a catheter may
be communicably attached to an opening that allows for the

duce a bolus of a substance, such as a drug. For example, a

catheter used in a method of the invention may be placed

45

delivery of drug to the target site.
“Drug delivery apparatus” as used herein includes but is

within a tissue or organ such that the catheter so implanted is
intended to remain at the site of implantation for some

not limited to, a drug reservoir and/or a drug pump of any
kind, for example an osmotic pump, an electromechanicl

extended period of time. Some of the drug delivery appara

pump, an electroosmotic pump, an effervescent pump, a

tuses that may be used in the methods of the invention, for

example the drug pumps and/or catheters, are designed to be

50

such a pump is implanted within the body.
Throughout this speci?cation, reference to the term
“GDNF” or the phrase “GDNF protein product” or “GDNF
polypeptide”, all of which are used interchangeably, refers to

implanted for periods greater than a month and even years and

to deliver drug during this period. A drug delivery apparatus
may be implanted, for example, subcutaneously, or within a
tissue or organ, or within a body cavity such as the peritoneal

cavity, infraclavicular space, the thoracic cavity, the pelvic

55

preferably human, in native sequence or in genetically engi

implanted into a tissue, for example into brain tissue, and may
be af?xed in place by ?xing the catheter to another tissue,
60

are intended to encompass at least one of the following con

ditions or disorders: Parkinson’s disease, neuronal dopamine

neered variant form, including, without limitation, biologi
cally active fragments, analogs, variants, (including, inser
tion, substitution, and deletion variants) and derivatives
thereof, and from any source, whether natural, synthetic, or

recombinantly produced.

The phrases “dopaminergic dysfunction”, “dopaminergic
dysregulation”, “dopaminergic degeneration”, “dopamine
depleted”, “dopamine de?cient”, or grammatical equivalents
thereof, may be used interchangeably herein. All such phrases

glial cell line-derived neurotrophic factor from any species,

including murine, bovine, ovine, porcine, equine, avian, and

cavity, or any other cavity or location that is convenient for
delivery of the intended substance. A catheter may be

such as bone, e.g., the skull, or cartilage, using an adhesive or
screws, clamps, sutures or any other suitable ?xing means.

hydraulic pump, a piezoelectric pump, an elastomeric pump,
a vapor pressure pump, or an electrolytic pump. Preferably,

65

Exemplary GDNF polypeptides useful in the present
invention include, without limitation, any of GDNF protein
products described in Us. Pat. Nos. 5,731,284, 6,362,319,
6,093,802, and 6,184,200 (all of which are hereby incorpo
rated by reference in their entireties). Preferred GDNF pro
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tein products for use in the methods of the present invention
include, but are not limited to, r-metHuGDNF, a recombinant
GDNF protein produced in E coli which has an amino acid

buffer components are water soluble materials such as phos

phoric acid, tartaric acids, lactic acid, succinic acid, citric

acid, acetic acid, ascorbic acid, aspartic acid, glutamic acid,
and salts thereof.
The primary solvent in a vehicle may be either aqueous or
non-aqueous in nature. In addition, the vehicle may contain

sequence identical to native mature human GDNF with the
addition of an amino terminal methionine. Thus, r-metH
uGDNF consists of 135 amino acids. Seven of the amino
acids are cysteines, which are involved in one intermolecular
disul?de bond and three intramolecular disul?de bonds. In its
active form, r-metHuGDNF is a disul?de-bonded

other pharmaceutically-acceptable excipients for modifying
or maintaining the pH, osmolarity, viscosity, clarity, color,
sterility, stability, rate of dissolution, or odor of the formula
tion. A preferred pharmaceutical composition of GDNF com

homodimer. The primary amino acid sequence of monomeric
r-metHuGDNF (SEQ ID NO: 1) is provided in Table 1.

prises a therapeutically effective amount of at least one

GDNF protein and a pharmaceutically acceptable vehicle.
More preferably, the pharmaceutically acceptable vehicle is
an aqueous buffer. More preferably, the vehicle comprises

TABLE 1
Amino 15
Primary Amino Acid Sequence

Ac id
No .

sodium chloride at a concentration of about 100 mM to about
200 mM and sodium citrate at a concentration of about 5 mM

to about 20 mM. Even more preferably, the vehicle comprises
HZN—Met

Ser Pro

Asp Lys

Gln

Met Ala Val Leu Pro

10

Arg Arg

GluArg

Asn

Arg GlnAla Ala Ala

20

AlaAsn

Pro Glu

Asn

SerArg Gly Lys Gly

30

Arg Arg

GlyGln

Arg

Gly Lys Asn Arg Gly

40

Cys Val

Leu Thr

Ala

Ile His LeuAanal

50

20

tration of about 150 mM and about 10 mM, respectively. Most

preferably, the GDNF pharmaceutical composition is formu
25

Thr Asp

Leu Gly

Leu

Gly Tyr Glu Thr Lys

6O

Glu Glu

Leu I le

Phe

Arg Tyr Cys Ser Gly

70

Ser Cys

Asp Ala

Ala

Glu Thr Thr Tyr Asp

8O

Leu Lys

Asn

LeuSer Arg Asn Arg

Arg Leu

Val Ser

Asp

Lys Val Gly GlnAla lOO

Cys Cys

Arg Pro

Ile

Ala PheAsp Asp Asp 110

Leu Ser

Phe Leu

Asp

Asp Asn Leu Val Tyr

His Ile

LeuArg

Lys

His SerAla Lys Arg 130

Cys Gly

Cys I le

COOH

90

120

lated as a liquid with 10 mM sodium citrate and 150 mM
sodium chloride at a pH of5.0.

The GDNF pharmaceutical composition may contain still
other pharmaceutically-acceptable formulation agents for
modifying or maintaining the rate of release of GDNF protein
30

Lys Ile

sodium chloride at a concentration of about 125 mM to about
175 mM and sodium citrate at a concentration of about 7.5
mM to about 15 mM. Even more preferably, the vehicle
comprises sodium chloride and sodium citrate at a concen

35

product. Such formulation agents are those substances known
to artisans skilled in formulating sustained release formula
tions. For further reference pertaining to pharmaceutically

and physiologically acceptable formulation agents, see, for
example, Remington’s Pharmaceutical Sciences, 18th Ed.
(1990, Mack Publishing Co., Easton, Pa. 18042) pages 1435
1712 (the disclosure of which is hereby incorporated by ref

erence).
Once the therapeutic composition has been formulated, it
may be stored in sterile vials as a solution, suspension, gel,

134

emulsion, solid, or dehydrated or lyophilized powder. Such
40

formulations may be stored either in a ready to use form, a

The GDNF protein products useful in the present invention

lyophilized form requiring reconstitution prior to use, or a

may be isolated or generated by any means known to those

liquid form requiring dilution prior to use. Preferably, the
GDNF pharmaceutical composition is provided in sterile

skilled in the art. Preferably, GDNF is recombinantly pro
duced. In a preferred method, the GDNF is cloned and its
DNA expressed, e.g., in mammalian cells or bacterial cells.

45

single-use vials at a concentration of 10 mg/mL and stored at
a temperature of —2-80 C. until use. Immediately prior to

Exemplary methods for producing GDNF protein products

administration, the GDNF protein product should be thawed

useful in the present invention are described in US. Pat. Nos.

and appropriately diluted with a sterile citrate buffered saline

6,362,319, 6,093,802 and 6,184,200 (all ofwhich are hereby
incorporated by reference in their entireties).
GDNF pharmaceutical compositions typically comprise a

(pH 5.0) consisting of 150 mM sodium chloride and 10 mM
50

sodium citrate.
In the methods of the present invention, GDNF is chroni
cally administered to a site of dopaminergic dysfunction in

therapeutically effective amount of at least one GDNF protein
product and one or more pharmaceutically and physiologi

the human brain by means of an implantable pump and one or

cally acceptable formulation agents. Suitable formulation

more catheters. The region of a PD patient’ s brain targeted for

chronic delivery of GDNF may be determined by assessing

agents include, but are not limited to, antioxidants, preserva

tives, coloring, ?avoring and diluting agents, emulsifying
agents, suspending agents, solvents, ?llers, bulking agents,
buffers, vehicles, diluents, excipients and/or pharmaceutical
adjuvants. For example, a suitable vehicle may be, physi
ological saline solution, citrate buffered saline, or arti?cial
CSF, possibly supplemented with other materials common in
compositions for parenteral administration. Neutral buffered

55

size of dopamine neuronal cells 3) dopamine metabolite lev

els 4) dopamine storage, 5) dopamine transport, 6) neuronal
dopamine uptake, 7) dopamine transporter binding, 8) quan
60

saline or saline mixed with serum albumin are further exem

plary vehicles. Those skilled in the art would readily recog
nize a variety of buffers that could be used in the composi
tions, and dosage forms used in the invention. Typical buffers
include, but are not limited to pharmaceutically acceptable
weak acids, weak bases, or mixtures thereof. Preferably, the

biomarkers of PD disease or disease progression including,
but not limited to, the number of TH expressing neurons 2)

tal size of terminal dopamine release, 9) rate of dopamine
turnover, 10) TH+ cell count, 11) TH+ innervation density
and 12) TH+ ?ber density. For instance, GDNF may be
infused directly into a region of the human brain which is

65

severely dopamine depleted. The region of a PD patients
brain which is severly dopamine depleted and, therefore, a
target for chronic delivery of GDNF may be determined by
neuroimagery of the brain, or regions thereof. The neuroim

US 8,946,152 B2
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agery technique used to determine the site of chronic infusion
of GDNF may be selected from the group consisting of 18F

catheter or catheter system useful in the context of the present
invention includes, but is not limited to, an intraparenchym al
infusion catheter or catheter system described in International

?uorodopa positron emission tomography (1 8F-dopa PET) 13,
l 23 1-26 -carboxymethoxy-3 [3 -(4-iodophenyl)tropane uptake

Patent Application Publication No: WO 02/07810, WOO3/

on single-photon emission tomography (123I-[3-CIT SPECT),

002170, or WO 03/077785, or U.S. Pat. Nos. 5,720,720,

and similar techniques. In a preferred embodiment of the
present invention, GDNF is infused directly into at least one

6,551,290, 6,093,180 or 6,609,020. The entire disclosure of
each of these Patent Applications and United States patents is

dopaminergic dysfunctional putamen of a PD patient. Even
more preferably, GDNF is infused directly into the posterior
region of at least one dopaminergic dysfunctional putarnen of
a PD patient. Mo st preferably, GDNF is infused directly into
at least one dopaminergic dysfunctional postero-dorsal puta

hereby incorporated by reference into this speci?cation.
The methods of the present invention are also achievable

by infusion of GDNF utiliZing a multiport catheter. A multi
port catheter is a catheter having a plurality of infusion holes
or ports disposed along the length of the catheter or catheter
tip. Generally, a multiport catheter will have said infusion

men of a PD patient.

holes or ports longitudinally spaced along the tip length at
substantially regular intervals. A multiport catheter therefore

A number of drug delivery apparatus, catheters, catheter
systems and combinations thereof have been developed for
the dispensing of medical substances to speci?c sites within

may have about 20 to about 60 ports, about 30 to about 50
ports, or about 35 to about 45 ports, along its length or the

the body and are all readily available to those skilled in the art
for use in the methods of the present invention. Therefore, one

may use prior art drug delivery devices, catheters, and cath
eter systems for delivering the GDNF compositions to the
target site of the brain of the patient at speci?ed concentra
tions and/or at speci?ed times and/or at different delivery
rates. By way of illustration and not limitation, in the methods
of the present invention one may use the technology
described in Us. Patent Publication No. US20030120262,

length of the catheter tip. A catheter useful in the methods of
the present invention includes, but is not limited to, an intra
20

4 per 0.5 mm placed approximately every 90°, about 5 mm

length, such as model #10532, manufactured by Medtronic,
Inc. (Minneapolis, Minn.), or any catheter substantially simi
25

US20030208184, or US20030225372 or U.S. Pat. Nos.

4,931,050, 4,838,887, 5,207,666, 4,714,462; 5176,641;
3,923,060, 4,003,379, 4,588,394, 4,447,224, 5,575,770,

lar thereto.
In another embodiment of the methods of the present
invention, in conjunction with any of the above or below
embodiments, a therapeutically effective dose of GDNF is
infused directly into one or both putamen of a human PD

4,978,338, 5,908,414, 5,643,207, 6,589,205 or 6,592,571.
The entire disclosure of each of these U.S. Patent Applica

putamenal (IPA) multiport catheter having 40 ports arranged

30

patient. The phrase “therapeutically effective dose” or “phar
maceutically effective dose”, which are used interchangeably

tions and Us. Patents is hereby incorporated by reference

herein, refers to that amount of GDNF suf?cient to result in

into this speci?cation. A preferred drug delivery apparatus

any amelioration, impediment, prevention or alteration of any
biological symptom generally associated with a neurodegen
erative disorder including, without limitation, PD by one

useful in the context of the present invention includes one

described in Us. Pat. No. 5,752,930 or U.S. patent applica

tion No. US20030216714 (which are hereby incorporated by
reference in their entireties). A more preferred drug delivery

35

apparatus useful in the context of the present invention
includes one described in Us. Pat. No. 6,620,151 (which is

hereby incorporated by reference in its entirety). An even
more preferred drug delivery apparatus useful in the context

40

application No. US20030216714 (which is hereby incorpo
rated by reference in its entirety). Most preferably the drug

men/ day to about 75 ug/putamen/ day. Even more preferably,

delivery apparatus used in the context of the present invention

GDNF is infused directly into a human putamen at a dose of
45

4,692,147, (which are hereby incorporated by reference in
their entireties) commercial embodiments thereof including,
but not limited to, the Synchromed® I, Synchromed® EL,
and Synchromed® II infusion pumps (Medtronic, Inc., Min

neapolis, Minn).

about 45 ug/putamen/ day. Even more preferably, r-metH
uGDNF is infused directly into a human putamen at a dose of
50

about 35 ug/putamen/ day. Mo st preferably, r-metHuGDNF is
infused directly into a human putamen at a dose of about 30
55

ug/putamen/day.

60

Applicants also disclose herein the use of a pharmaceuti
cally effective amount of GDNF including, but not limited to,
r-metHuGDNF, and at least one pharmaceutically acceptable
vehicle, excipient, or diluent in the preparation of a pharma
ceutical composition for treating cognitive disorders or inhib

iting cognitive decline associated with neurodegenerative
disorders, including, without limitation, PD and dementia,

sure of these U.S. patent applications and the United States

patent is hereby incorporated by reference into this speci?
cation.
The methods of the present invention are also achievable

by infusion of GDNF utiliZing a single port catheter. A single
port catheter is a catheter having one hole or port, generally
disposed at the distal end of the catheter. Accordingly, a

about 25 ug/putamen/day to about 40 ug/putamen/ day. Even
more preferably, r-metHuGDNF is infused directly into a
human putamen at a dose of about 30 ug/putamen/day to

oped for the dispensing of agents, such as drugs, to speci?c

invention one may use the technology described in Us.
Patent Publication No. 20030216700, 20030199831, or
20030199829 or U.S. Pat. No. 6,319,241. The entire disclo

about 15 ug/putamen/day to about 50 ug/putamen/ day. Even
more preferably, r-metHuGDNF is infused directly into a
human putamen at a dose of about 20 ug/putamen/day to

In another embodiment of the present invention, in con
junction with any of the above or below embodiments, a
number of catheters and catheter systems have been devel

sites in the body and are readily available to those skilled in
the art for use in the methods of the present invention. By way
of illustration and not limitation, in the methods of the present

putamen at a dose of about 5 ug/putamen/day to about 50

ug/putamen/day. Even more preferably, GDNF is infused
directly into a human putamen at a dose of about 10 ug/puta

of the present invention includes one described in Us. patent

is one described in Us. Pat. Nos. 4,146,029, 4,013,074, or

skilled in the relevant art. In a preferred embodiment of the

present invention, in conjunction with any of the above or
below embodiments, GDNF is directly into a human putamen
at a dose of about 1 ug/putamen/day to about 100 ug/putamen/
day. More preferably, GDNF is infused directly into a human
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wherein the composition is for administration to one or both
putamen of a human in need thereof via convection-enhanced
infusion using at least one implantable pump and at least one
catheter. In a preferred use of a pharmaceutically effective
amount of GDNF and at least one pharmaceutically accept

US 8,946,152 B2
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able vehicle, excipient, or diluent in the preparation of a

EXAMPLES

pharmaceutical composition for treating cognitive disorders
The following examples, including the experiments con

or inhibiting cognitive decline associated with neurodegen
erative disorders, including, without limitation, PD and

ducted and results achieved are provided for illustrative pur
poses only and are not to be construed as limiting the inven
tion.

dementia, the composition is for administration to a site of
dopaminergic dysfunction within one or both putamen of a
human in need thereof via convection-enhanced infusion
using at least one implantable pump and at least one catheter.

Example 1

For such uses dopaminergic dysfunction is pre-operatively. In
another embodiment of the present invention, in conjunction

Unilateral Intraputamenal GDNF Improves Bilateral
Motor Functions in Patients with Parkinson’s
Disease

with any of the above or below embodiments

The inventive method has the effect, upon application to

Methods

parkinsonian patients, of signi?cantly reducing symptoms of

Subjects

Parkinson’s disease, the resulting improved condition of the
patient continuing for at least 30 months. In particular, a clear
improvement of disease-speci?c symptoms was obtained
with the inventive method insofar as motoricity, ?ne motor

icity, and ?ne dexterity. In addition, mobility and concentra
tion power was increased and reaction time was decreased.

20

son’s disease: A clinicopathologic study?, Neurology,

Pronunciation, facial expressiveness, posture, sense of smell,

42: 1 142-1 146 (1992)). Eightmen and two women, aged 47 to
70 years (see Table 2), with moderate to severe idiopathic PD

libido, sexual function, and emotional condition were
improved and state of mind was brightened.

In yet another embodiment of the present invention, GDNF

25

can be used as a cognitive enhancer, to enhance learning,

cognitive decline and/or dementia, for example, in patients
with PD. Alzheimer’s disease, which has been identi?ed by

fastest growing segment of the US. population), have Athe
imer’s disease. Twenty-?ve percent of all patients with Par

30

dependence/abuse, and inability or unwillingness to comply
with long-term follow-up. Premenopausal subjects had to
agree to abstinence or use of barrier methods of birth control

during the study unless surgically sterile. No patients had had
35

prior exposure to neuroleptics or used selegiline for two
months prior to implantation of the catheter. For the two

months prior to the study patients had had stable symptoms

kinson’s disease also suffer from Atheimer’s disease-like
dementia. Applicants have shown here for the ?rst time that

chronic intraputaminal administration of GDNF has applica
tion in treating or preventing cognitive disorders in humans.
In particular, intraputaminal administration of GDNF has
application in treating or preventing cognitive disorders and/

(Hoehn and Yahr Stage 3-4) were selected for the study.
Primary symptoms were rigidity and bradykinesia with dis
ease duration ranging from 4.8 to 15.4 years (Table 2). Exclu
sion criteria included the presence of clinically signi?cant
depression or dementia, concomitant disease likely to inter
fere with the study, prior surgery for PD, drug or alcohol

particularly as a result of dementias or trauma, or to inhibit

the National Institutes of Aging as accounting for more than
50% of dementia in the elderly, is also the fourth or ?fth
leading cause of death in Americans over 65 years of age.
Four million Americans, 40% of Americans over age 85 (the

Consent from the patients described in Example 1 was
obtained in accordance with the FDA and the local University
of Kentucky Medical Center Internal Review Board regula
tions and guidelines. Patients were diagnosed with idiopathic
PD according to standard criteria (Hughes, A. 1., et al., What
features improve the accuracy of clinical diagnosis in Parkin

and had been maintained on a constant regimen of anti-PD

medications consisting of L-dopa and/ or a dopamine agonist
40

or Alzheimer’s disease-like dementia associated with PD.

(range 300-2500 mg/day levodopa equivalents, see Nutt, J.
G., et al., (2003)); a catechol-o-methyltransferase inhibitor
(COMT) had been used by two subjects and amantadine by
two patients. No changes were made inpatients’ anti-PD drug
regimens during the course of the study.
TABLE 2
Patient Data, Side-Effects, and Other Effects of GDNF

Patient #

Age (years)
Duration of disease (years)

L—Dopa equivalents/day
Change in medications after 6 mo.
Taste Abnormalities
Lherrnitte’s

Hyponatraerrnia
Improved Bladder Control
Recovery of Sexual Function
Improvement in Taste/ Smell
Reduction in Hypomimia *(Off)*

+

Reduced Hypophonia (Off and On)*
Improved Postural Stability (Off)*

+
+

Decreased End—of—Dose Fluctuations*

+
+

+

+

+
+

+

+

+

Decreased Dyskinesia*

+

DELIVERY SYSTEM EFFECTS

Headaches

MRI Changes

+

+

+

+

+

Pump Related Discomfort

+

+

+

+

+
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TABLE 2-continued
Patient Data, Side-Effects, and Other Effects of GDNF
Patient #

Age (years)
Duration of disease (years)
L—Dopa equivalents/day

6

7

8

9

10

50
4.8
700

63
6.2
1775

69
12.2
1200

68
11.8
2500

47
6.8
500

+

+

+

+

+

+

+

+

Change in medications after 6 mo.
Taste Abnormalities
Lhermitte’s

+
+

Hyponatraemia
Improved Bladder Control
Recovery of Sexual Function
Improvement in Taste/ Smell
Reduction in Hypomimia *(Off)*

+

+

Reduced Hypophonia (Off and On)*
Improved Postural Stability (Off)*

+
+

+
+

Decreased End—of—Dose Fluctuations*

+

Decreased Dyskinesia*
DELIVERY SYSTEM EFFECTS

+

Headaches

+

+

+

+

+

MRI Changes
Pump Related Discomfort

+
+

+
+

+
+

+
+

+
+

Duration of disease is from onset ofsymptoms to week prior to surgery. L-Dopa Equivalents based on Nutt, .I.

G., et al., (2003). Reduction in hypomimia (question 19, section 3 UPDRS). Reduced hypophonia (question 5,
section 2 and question 18, section 3 UPDRS). Improved postural stability (questions 29 & 30, section 3
UPDRS). Decreased end of dose ?uctuations (questions 36-39, section 4 UPDRS). Decreased dyskinesia

(questions 32-34, section 4 UPDRS).

Surgical Procedures
Each patient had an MRI-based stereotactic implantation
of an intraputamenal (IPA) multi-port catheter (1 .65 mm O.D.
diameter, 40 holes, 4 per 0.5 mm placed every 90°, 5 mm

same amount of ?uid (133 pl) per day. After 24 weeks of
infusion, the remaining r-metHuGDNF was removed from
30

length; Medtronic, Inc., Model #10532) and SynchroMed®
pump (Medtronic, Inc., Model #8626L-18) contralateral to
the most affected side (see FIG. 1(a) and FIG. 1(b)). For each
patient, a Leksell headframe was applied and a 1 mm slice

35

the pump and the pump was ?lled with CBS. Due to the slow

drug infusion rate, and the length of catheter tubing between
the pump and the tip of the putamenal catheter, it takes
approximately one week for r-metHuGDNF in the tubing to
clear. Therefore, a total washout period of ?ve weeks was
needed to assess the effects of four weeks of trophic factor

MRI scan was performed. Targeting of the catheter placement
was achieved using the Leksell Surgi Plan® (Copyright©
1991 -2003 Elekta Instruments AB Stockholm, Sweden). Fol

withdrawal. After the drug washout, patients had the option of
reinstating GDNF treatment at the highest previous tolerated

lowing standard stereotactic surgical procedures, the IPA

continuation of the GDNF infusions.

catheter was inserted into the medial putamen. The citrate

dose level for an extended period. All ten subjects requested
40

buffered saline-primed infusion pump was implanted subcu

Clinical Testing and Follow Up
Clinical evaluations were based on 1) UPDRS Total ON

taneously in the ipsilateral lower quadrant abdominal wall

and OFF Scores, 2) UPDRS Motor ON and OFF Scores and

and a catheter was tunneled to connect the pump to the ind

3) the Clinical Assessment Program for Surgical Interven
tional Therapies in Parkinson’s Disease CAPSIT-PD (Defer,
G-L., Core assessment program for surgical interventional
therapies in Parkinson’s disease (CAPSIT-PD). Mov Dis.,
14:572-584 (1999)). All patients were evaluated using total

welling IPA catheter. Locations of all catheters are schemati

cally shown in FIG. 1(a). A schematic of the infusion system

45

is seen in FIG. 1B. A postoperative MRI and posterior-ante
rior and lateral x-rays of the skull, chest and abdomen were
performed 24 hours after surgery to con?rm placement of the

UPDRS and CAPSIT-PD timed motor tests, and were

catheter tip, continuity of the connections, and to detect puta
menal hemorrhage. All catheters were seen to be within the

50

putamen (see FIG. 1a).
GDNF Treatment

The recombinant-methionyl human glial cell line-derived
neurotrophic factor (r-metHuGDNF) was prepared by
Amgen, Inc. (Thousand Oaks, Calif.). The r-metHuGDNF

requested to keep a personal diary. Required visits were
scheduled weekly during the ?rst fourweeks of the study after
pump implant. Thereafter, visits were scheduled monthly
through the 24 weeks of GDNF therapy with a ?nal follow-up
visit to assess the effects of GDNF washout.

55

Statistical Methods
For the UPDRS endpoints, comparison of mean responses

was stored in single-use vials in a buffer of 10 mM citrate and

across time was based on a linear mixed model with post hoc

150 mM sodium chloride (CBS) at pH 5.0. At implantation,

comparison of means based on Fisher’s protected least sig
ni?cant differences procedure. Con?dence intervals for the
percent change from baseline to the 24 week follow-up were

the pump was ?lled with preservative-free CBS and pro
grammed to infuse at 133 uL/day and pump re?lls occurred
monthly. The pump was programmed to infuse at a continu
ous basal infusion rate of 2 ul/hour. Small bolus injections

60

(21.3 ul delivered in 117 seconds) were delivered every 6
hours to supplement the basal rate and to increase the brain
area affected by the drug. At the end of week four post sur
gery, r-metHuGDNF infusion began, with dose escalations at

obtained by the delta method and are based on a t-distribution

with 9 degrees of freedom. For the CAPSIT-PD endpoints

65

some patients could not complete some tasks in which case a
score of 90 seconds was assigned to the Stand-Walk-Sit task
and 30 seconds was assigned to the Hand-Arm movement
test. Comparison of the distribution of responses was based

eight week intervals from 3 ug/day to 10 ug/day to 30 ug/day.

on Friedman’s chi-square statistic with post hoc comparison

Solution concentrations of GDNF were adjusted to deliver the

of means based on Fisher’s protected least signi?cant differ

US 8,946,152 B2
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ences procedure applied to the ranks across time determined
on a patient by patient basis. Control of the Type I error rate
for testing each week of follow-up to the baseline week was

out. In addition, eight patients showed improved postural
stability in OFF, seven reported decreased end-of-dose ?uc

tuations and three experienced decreased dyskinesia (Table
2). Other motor/ sensory improvements included reduced
hypophonia (OFF and ON) in six patients, reduced hypo
mimia in eight patients and improved taste and smell reported
by one patient (Table 2). The observed reduction in bradyki

obtained by applying the Bonferroni-Holm procedure (Holm,
S. A simple sequentially rejective multiple test procedure.
Scand. J. Statistics, 6: 65-70 (1979)). Statistical signi?cance
was determined at the 0.05 level.

Results
Testing was conducted in an operationally-de?ned OFF
condition: (i) anti-PD medications withheld for 2.5 times the

nesia was supported by the CAPSIT-PID measures of timed
Hand-Arm and SWS tests. The results of testing in the OFF

duration of each drug’ s predicted serum half life, and (ii) prior
to the subject’s ?rst dose of medication on the day of testing.
Total UPDRS scores were signi?cantly improved by 16, 20
and 33% in the OFF condition at 8, 16, and 24 weeks, respec
tively (Table 3). Total UPDRS scores in the ON condition
were also improved by 26, 23, and 34% at 8, 16, and 24 weeks
post-GDNF, respectively. ON testing was performed within

ments including balance and gait were measured in SWS
testing and were improved by 26% in OFF at six months
post-GDNF. Bilateral improvements were also evident in the
Arm-Hand test measuring movement speed between two
points 30 cm apart. Performance times of the Arm-Hand test

and ON condition are seen in Table 3. Bilateral axial move

were signi?cantly faster in both ON and OFF on both the

contralateral and ipsilateral sides to
TABLE 3
GDNF Improves UPDRS and CAPSIT Measures
8 WEEKS

Tests

BASELINE

Total
UPDRS
Motor
UPDRS
CAPSIT
Stand,Wa1k, Sit
CAPSIT
Contralateral

OFF
ON
OFF
ON
OFF

Hand/Arm
CAPSIT
Ipsilateral
Hand/Arm

r
r
r
r
r
r
r
r

<.0001
0.0005
0.0004
0.0201
0.0464

ON
OFF
ON

0.1032
0.0002
0.0004

54
35
35
15
37
19
15
12

3 (—14%)
3 (—17%)
2 (—8%)

0.011
0.0011
0.029
0.0075
0.1741
i
0.0792
0.2680

OFF
ON

15 r 2
12 r 2

0.0005
0.0005

12 r 1 (—20%)
10 r 1 (—17%)

0.0348
0.0242

r4
r5
r3
r4
r7

4 (—16%)
3 (—26%)
3 (—13%)
3 (—35%)
10 (—5%)

24 WEEKS

10 pg/day
51
36
32
16
29

r
r
r
r
r
r
r
r

P+

5
3
4
2
8
5
2
2

16 WEEKS

OFF
ON
OFF
ON
OFF

3 rig/day

64
47
40
23
39
22
18
13

Tests
Total
UPDRS
Motor
UPDRS
CAPSIT

P*

P++

(—20%)
(—23%)
(—20%)
(—30%)
(—26%)

0.0014
0.023
0.0034
0.0166
0.0491

30 pg/day
43
31
28
16
29

r5
r4
r4
r4
r9

P+++

(—33%)
(—34%)
(—30%)
(—30%)
(—26%)

0.0001
<0.0001
<0.0001
0.0090
0.0012

WASHOUT
53
34
33
14
31

r4
r4
r3
r3
r8

(—19%)
(—30%)
(—18%)
(—39%)
(—21%)

P++++
0.0037
0.0004
0.0038
0.0027
0.0491

Stand,Wa1k, Sit

ON

15 r 1 (—32%)

i

14 r 1 (—36%)

i

14 r 1 (—32%)

i

CAPSIT
Contra-lateral

OFF
ON

12 r 2 (—43%)
9 r 1 (—31%)

0.0037
<.0001

10 r 2 (—44%)
8 r 2 (—38%)

<.0001
<0.0001

14 r 3 (—22%)
10 r 2 (—23%)

0.0009
0.0010

OFF
ON

10 r 1 (—33%)
8 r 1 (—33%)

<.0001
<.0001

9 r 1 (—40%)
8 r 1 (—33%)

<0.0001
<0.0001

11 r 1 (—27%)
8 r 1 (—33%)

0.0004
<.0001

Hand/Arm
CAPSIT
Ipsilateral

Hand/Arm
Baseline UPDRS scores for each patient are the means ofthree pre-GDNF determinations at —1 , +1 and +4 weeks following catheter
implantation. UPDRS measures are means i SEM. CAPSIT measures are in seconds i SEM.

*P value for comparing response across time.
P values for post hoc comparisons: + 8 weeks vs. baseline; ++ 16 weeks vs. baseline; +++ 24 weeks vs. baseline; ++++ washout vs.

baseline

six hours after the subject’s ?rst dose of anti-PD medic ation
for the day. These improvements were maintained over the
?ve weeks after discontinuation of the highest-dose infusion

TABLE 4
55

95% Con?dence intervals after 24 weeks of GDNF therapy

(30 mcg/ day). The 95% con?dence intervals (CI) for %

95% CI

change from baseline at 24 weeks are given in Table 4, which
support the clinical signi?cance of the GDNF effects at 24
weeks. UPDRS (Part III) Motor scores in OFF were also

signi?cantly improved by 13, 20, and 30% at 8, 16, and 24

60

Endpoint

State

% Improvement

Low

High

Total UPDRS
Total UPDRS
Motor UPDRS
Motor UPDRS

Off
On
Off
On

33%
34%
30%
30%

18%
1 6%
15%
5%

47%
51%
48%
61%

weeks post-GDNF, respectively. UPDRS Motor scores in ON
were seen to be signi?cantly improved by 35, 30, and 30% at
8, 16, and 24 weeks post-GDNF, respectively. The 95% con
?dence intervals (CI) for % change from baseline at 24 weeks
Con?dence intervals for percent change from baseline to
are given in Table 4, which support the clinical signi?cance of 65 improvement in Table 4 at 24 weeks,
the GDNF effects at 24 weeks. UPDRS Motor scores

the site of intraputamenal infusion, with signi?cant improve

remained signi?cantly improved in OFF and ON after wash

ments ranging from 31-44% at 16 and 24 weeks post-GDNF.

US 8,946,152 B2
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Safety and Side Effects
The unilateral pump implantation procedure was safe, with
few adverse events reported by all ten patients (Table 2).

uGDNF delivery. The remaining patients (P2-5) had bilateral
disease and bilateral putamenal implantations of delivery sys

There was general discomfort from the pump, which was

tems. The precise region of the dorsal putamen to be targeted
for infusion was determined by co-localization studies using

experienced by all ten subjects immediately following sur
gery and sporadically thereafter. All patients experienced

port catheters were placed into the dorsal putamen, the site of

headaches the day following surgery, which resolved and did

maximal loss of 18F-?uorodopa signal (con?rmed by PET in

not reoccur. The MRI changes consisted of a halo of increased

all subjects). Pump placement and stereotactic surgery were
tolerated well by all patients. However, there were some

18F-dopa PET and MR images. Under MRI guidance, single

signal intensity on T2-weighted images less than 1 cm in
thickness around the catheter. There was no change in body

complications. P1 required perioperative repositioning of the

weight during the trial. Adverse event frequencies were: cath

catheter to center exactly within the dorsal putamen. This was
achieved successfully on a second pass during the surgical

eter re-placement (1/ 10), infection (0/10), pump failure

procedure. In addition, patient 4 developed a wound infection

(0/ 10), hemorrhage (0/ 10), blood chemistry abnormalities
(0/ 10) and delivery system complications/disconnections

related to the pumps and connection tubing that was success

(0/ 10). Two subjects reported transient Lhermitte’s symp

fully treated with explantation of the extracranial devices,

toms on 1-2 occasions. None of the subjects reported nausea,
anorexia, vomiting or weight change as was seen by Nutt, et

antibiotics and re-implantation within 4 weeks.
Patients
Five PD patients were included in this pilot study. Ethical
approval was obtained from the local ethics committees both
at Frenchay Hospital and the Hammersmith Hospitals Trusts
and all participants signed full consent forms. All patients
were diagnosed as suffering from idiopathic PD according to
standard criteria (brain bank criteria). Patients were selected
for surgery when they were suffering signi?cant functional

al., (2003). In addition, none of our ten subjects experienced
hyponatraemia or alterations in antidiuretic hormone (ADH).
The sustained improvements in all ten subjects are consis
tent with extensive preclinical data suggesting GDNF e?i
cacy in treating PD. The 95% con?dence limits for the total
and motor UPDRS scores in ON and OFF further support the
clinical signi?cance of the results. Decreases over baseline in
the total and motor UPDRS scores after one-month washout
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impairment despite optimal medical therapy. Exclusion cri
teria included women of child-bearing age, age over 65, the

indicate that the positive effects of GDNF may persist for at
least four weeks after GDNF withdrawal. However, these

presence of clinically signi?cant depression, or systemic dis

persistent gains may be less in magnitude compared to the

ease or inability or unwillingness to comply with long-term

maximum bene?t observed during active GDNF infusion.
This is consistent with prior studies in animal models of PD

follow-up.
Surgery
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(Grondin, R., et al., (2002); Grondin, R., et al., (2003),
Hebert, M. A., (1997)).

Sub cortical nuclei were localized and targeted using high
resolution MR images acquired under strict stereotactic con

Sustained and consistent placebo effects do not typically
occur in PD subjects (14, 15) and patients with PD do not
spontaneously improve over time making these confounds
less likely explanations for the time course of improvements

ditions. Under general anesthesia, a modi?ed Leksell stereo
tactic frame was a?ixed parallel to the orbito-meatal plane.
35

The anterior (AC) and posterior (PC) commisures were iden
ti?ed in a mid-sagittal planning scan. Axial images 2 mm

thick were acquired parallel to the AC-PC plane and coronal

we observed. Strikingly, signi?cant effects were observed in

all subjects receiving intraputamenal infusion of GDNF. Such

images orthogonal to these then obtained. Using magni?ed

consistent effects have not been seen in other treatments for

hard copies of the MRI scans the inversion recovery scans
were overlaid with the inverted T2 images to enhance the

PD such as DBS or fetal cell transplants (Krack, P., et al.,
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de?nition of the putamenal boundaries in both planes. Using

Five-year follow-up of bilateral stimulation of the subtha
lamic nucleus in advanced Parkinson’s disease, N. Engl. J.
Med., 349: 1925-1 934 (2003); Olanow, C. W., et al., A double
blind controlled trial of bilateral fetal nigral transplantation in

Parkinson’s disease,Ann. Neurol. 54:403-414 (2003)). Eight
subjects in this study showed improved postural stability, six
of the ten patients had improved speech (reduced hypopho

the PET images, the area of the postero-dorsal putamen with

the lowest 18F-dopa uptake was targeted for infusion; stereo
tactic target coordinates were recorded and a trajectory
45

general anesthesia. Under stereotactic conditions, 1 mm
diameter guide tubes were implanted to a point above the
putamen target over a guide rod. A 0.6 mm guide wire was

nia) and seven patients exhibited decreased hypomimia. The
quality of ON time was improved by decreased symptom
?uctuations in seven subjects. While dyskinesias were not

planned. The following day, surgery was performed under

introduced down the guide tube to target, following which the
50

patients underwent repeat MR/CT imaging to verify target

prominent in this patient group, they were reduced in three
subjects. All of the patients also reported an increased sense

localization. The guide wire was then replaced with a 0.6 mm
diameter catheter introduced to target. r-metHuGDNF

of well-being (manuscript in preparation), suggesting an

primed SynchroMed pumps (Medtronic Inc, Minneapolis)
were implanted in the upper abdominal region, subcutane

additional effect of intraputamenal GDNF.
55

Example 2
Treatment of Parkinson’s Disease in Humans with
Convection-Enhanced Infusion of GDNF into the
Putamen

cosmetic appearance. Catheters were tunneled connecting the
pumps to the indwelling 0.6 mm intraparenchymal brain cath
60 eters.

Convection-enhanced infusion into the targetted brain tis
sue was achieved in this study by pumping drug at a relatively

Study Design
Five patients with idiopathic, L-dopa responsive PD who
were poorly controlled on optimal medical therapy were

identi?ed. The ?rst patient (P1) had predominantly unilateral
disease affecting the left side and underwent contralateral
putamenal implantation of catheter and pump for r-metH

ously in the ?rst patient, and subfascially (beneath the ante
rior rectus sheath) in the subsequent cases; subfascial place
ment reduced the pump pro?le in the abdomen and improved
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high rate through the smallest possible catheter having a
single port at its distal end. Otherwise, drug emerging from a
single port in the distal end would tend to travel up the path of
least resistance, i.e., up the catheter/tissue interface. Because
the ?ow up this space is proportional to the radius squared,

US 8,946,152 B2
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even small increases in catheter size would be expected to

Health-Related Quality of Life Outcome Measurement and

reduce the resistance outside the catheter, therefore reducing
the pressure gradient and bulk ?ow into the tissue substan

Follow-Up

tially. Additionally, the smallest possible catheter is preferred

questionnaires: the 39-item Parkinson’s Disease Question
naire (PDQ 39) and the 36-item. Medical Outcomes Study

since catheter placement would be expected to cause tissue
trauma and local necrosis resistance to ?ow would be lower
along the catheter tract. Therefore, it follows that a smaller

catheter would result in less tissue damage and less drug
?owing back along the catheter tissue interface to the cortex
and entering the CSF space. On the other hand, with larger
catheters and slower infusion rates, ?uid penetration into the
tissues becomes solely dependent upon diffusion down a
concentration gradient, which due to the size of the GDNF
molecule will be very limited. This is supported by Chen et al.

Patients were also assessed using validated quality of life
5

short form health survey (SF-36) were used before surgery

and after 3, 6, 12, 18, and 24 months. Descriptive statistics
(mean, standard deviation, range, 95% con?dence interval)
were obtained for each variable. Comparisons over time were
10

Neuropsychological Evaluation and Follow-Up
Also evaluated were changes in medication (L-dopa

equivalents) requirement and neuropsychology, which con
tained tests of verbal intellect, verbal and visual memory,

(J. Neurosurg 90:315-320, 1999isee appendix), who dem

attention, executive function, anxiety and depression as has
been previously described (McCarter, R. 1., et al., Cognitive
functioning after subthalamic nucleotomy for refractory Par

onstrate in a rat model that infusing protein into the striatum
with a 0.4 mm catheter results in 5% loss of infusate through

leak back along the catheter, and by increasing the diameter to
0.6 mm, the loss increases to 35%. In this study, increasing the
infusion rate beyond about 6 pl per hour, increased leak back

20

and loss of infusate and infusate concentration had no effect
on the volume of distribution.
r-metHuGDNF Production and Infusion

the signi?cance of change over time in the rating scores. All

analyses were performed in SPSS. Four of the patients (all of
25

Inc. This protein was produced in Escherichia c0li cells that
contain an expression plasmid with a DNA insert encoding

the bilateral cases) underwent pre-operative neuropsycho
logical assessment. All ?ve patients were assessed at 12 and

24 months post implantation. The signi?cance of changes in
cognitive test performance was evaluated using con?dence

mature human GDNF, with an addition of an amino terminal

methionine. r-metHuGDNF is liquid formulated with 10 mM
sodium citrate and 150 mM sodium chloride at a pH of 5.0. It
was supplied in single-use vials at a concentration of 10

kinson’s disease. J. Neurol. Neurosurg. Psychiatry, 69: 60-66
(2000)). The battery of cognitive tests used was designed to
minimize the possible confounding effects of both slowness
of movement and movement dif?culty on cognitive test
results. Friedman’s Related Samples test was used to evaluate

Recombinant-methionyl human glial cell line-derived neu

rotrophic factor (r-metHuGDNF) was prepared by Amgen

made using Student’s paired-samples t test.
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intervals derived from the standard error of prediction around
the predicted true score at baseline (Lord, F. M. and Novick,
M. R. Statistical theories of mental test scores. Reading, MA:

mg/mL. Following implantation, the SynchroMed pumps

Addison-Wesley, (1968); Atkinson, L. Three standard errors

were programmed to deliver a continuous infusion of 14.4 pg

of measurement and the Wechsler Memory ScaleiRevised.

of r-metHuGDNF per putamen per day at rate of 6 pl per hour.
The pumps were re?lled monthly with fresh solution. The low

35

concentration of r-metHuGDNF was maintained for a period
of 8 weeks. At 2 months the pumps were re?lled with fresh

Psychological Assessment: A journal ofconsulting and clini
calpsychology, 3:136 -138 (1991)). A signi?cant change was
inferred if a score at either 12 or 24 months fell outside of the

con?dence interval of the baseline score (for the unilateral

solution of higher concentration and programmed to deliver

case the baseline score was at 12 months and change scores

43.2 pg of r-metHuGDNF per putamen per day at a rate of 6

were inferred for performance at 24 months). In addition, a

pl per hour. Providing good tolerance and no side effects, this

40

dose was to be maintained for the duration of the trial. How

PD control group consisting of 18 patients who had under
gone other forrns of surgery for PD was used to establish the
effect of repeat cognitive assessment over a 12 month period.

ever, due to the development of high-signal MRI changes of
uncertain signi?cance, the infusion parameters were altered
to deliver lower doses (10.8-14.4 pg of r-metHuGDNF) at
lower rates (2-6 pl per hour), in attempt to establish safe and

For each patient in this group two postoperative neuropsy

clinically effective parameters, with repeat MRI monitoring

chological assessments were available. This control group
was comparable with the GDNF patient group in terms of
years of education, age at surgery, duration of PD at surgery

at regular intervals. Between 12 and 18 months, all patients

and NART estimated FSIQ (p>0.05).

received a continuous infusion of 14.4 pg of r-metHuGDNF

Scanning Procedures and Image Analysis

per putamen per day at rate of 6 pl per hour. At 18 months the
dose of GDNF was increased to 28.8 pg per putamen per day

50

at rate of 6 pl per hour, and remained so until 24 months or
longer except in P4 who reverted back to 14.4 pg at 20
months.

Clinical Evaluation and Follow-Up
Clinical evaluations were based on the Core Assessment 55

Program for Intracerebral Transplantations (CAPIT) (Lang
ston, J . W. et al., Core assessment program for intracerebral

transplantations (CAPIT). Mov Disord., 7, 2-13 (1992)) a
validated protocol for evaluating surgical treatments of idio
pathic PD. All patients were evaluated on the Uni?ed Parkin

60

son’s Disease Rating Scale (UPDRS) and underwent timed
motor tests at baseline, 3, 6, 12, 18 and 24 months. Assess
ments were performed in both off and on medication states.

Before they were assessed off medication, patients fasted and
medications were withdrawn overnight. The same assess

ments were then repeated after administration of L-dopa
when the patients were “on”.
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18F-dopa PET provides a measure of synaptic amino acid
decarboxylase (AADC) activity and hence acts as an in vivo

marker of dopamine storage and the functional integrity of
dopamine terminals. Previous human and animal lesion stud
ies have demonstrated that striatal 18F-dopa PET correlates
with nigral cell numbers, dopamine content in striatal termi
nals (Garnett, et al., Dopamine visualized in the basal ganglia
of living man, Nature, 305: 137-138 (1983); Martin et al.,
Nigrostriatal function in humans studied with positron emis

sion tomography. Annals 0fNeur0l0gy, 26:535-542 (1989);
Brooks et al., Differing patterns of striatal 18F-dopa uptake in
Parkinson’s disease, multiple system atrophy, and progres
sive supranuclear palsy. Annals of Neurology, 28:547-555
(1990b); Pate et al., Correlation of striatal ?uorodopa uptake
in the MPTP monkey with dopaminergic indices. Annals of
Neurology, 34: 331-338 (1993) and the UPDRS off medica
tion (Morrish, et al., Measuring the rate of progression and

estimating the preclinical period of Parkinson’s disease with

[18F]dopa PET. Journal ofNeurology, Neurosurgery & Psy

US 8,946,152 B2
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chialry, 64: 314-319 (1998)), in particular, with the bradyki

catheter tip. The regions of interest were then used to sample
18F activity on the parametric image. In the 4 patients oper
ated on bilaterally, the mean Ki values for the left and right
regions of interest were averaged to produce one Ki value for
each of the ?ve ROIs per scan. Only the ROIs from the

nesia and rigidity sub scores (Otsuka, et al., Differences in the
reduced 18F-Dopa uptakes of the caudate and the putamen in
Parkinson’s disease: correlations with the three main symp

toms, Journal of the Neurological Sciences, 136: 169-173
(1996)). Furthermore, it is possible to demonstrate progres
sive decline of striatal 18F-dopa uptake in patients with PD
over time (Morrish, et al., 1998; Morrish, et al., An [18F]
dopa-PET and clinical study of the rate of progression in
Parkinson’s disease. Brain, 119 (Pt 2), 585-591 (1996)). 18F

operated right side of the patient who received unilateral
surgery were included in the analyses. The patient’s Ki values
were then subjected to a paired Student’s two-tailed t test.

Lack of Adverse Effects of r-metHuGDNF Infusion
Surprisingly, side effects due to r-metHuGDNF infusion

dopa PET was used here to assess striatal dopamine terminal

itself were very limited. There was no nausea, anorexia, vom

function in ?ve PD patients receiving chronic intra-striatal

iting or weight loss reported as in the previous intraventricu

GDNF infusions.

lar trial (Kordower, J. H. et al., 1999). There were no haema

The patients had 18F-dopa PET pre-operatively, and at 6,

tological or blood chemistry abnormalities. At the high dose

(43.2 ug/putamen/day), 3 subjects reported abnormalities of

12, 18, and 24 months postoperatively using an ECAT
EXACT RR++ camera (CTI/ Siemens 966; Knoxville, Tenn.)
in 3D acquisition mode following withdrawal from medica
tion for at least 12 hours. Patients received 150 mg of carbi

taste and smell (soapy or metallic), 2 subjects reported that
their dreams had become abnormally vivid, and 4 subjects
described a Lherrnitte’s phenomenon (tingling passing from

dopa and 400 mg of entacapone; 1 hour later 111 MBq of

the neck down through the arms and sometimes onto the trunk

1 8F -dopa in normal saline was administered as an intravenous 20

and down the legs provoked by neck ?exion). None of these

bolus at the start of scanning. The images were acquired in 3D
mode as 26 time frames over 94.5 minutes (1x30 seconds,
4><1 min, 3><2 min, 3><3 min and 15><5 mins). Parametric

effects necessitated immediate dose cessation or reduction,

and all remitted (except for occasional, mild Lhennitte’ s sign)

images of 18F-dopa in?ux constants (Ki) were generated from
time frames 25 .5 to 94.5 minutes post injection using in house
software based on the MTGA approach of Patlak and Blas

berg (Brooks, D. 1., The relationship between locomotor dis
ability, autonomic dysfunction, and the integrity of the striatal
dopaminergic system in patients with multiple system atro
phy, pure autonomic failure, and Parkinson’s disease, studied
with PET. Brain, 113 (Pt 5) 1539-1552 (1990a); Rakshi, J. S.
et al., Frontal, midbrain and striatal dopaminergic function in
early and advanced Parkinson’s disease A 3D [(18)F]dopa
PET study. Brain, 122 (Pt 9): 1637-1650 (1999); Patlak, C. S.
& Blasberg, R. G., Graphical evaluation of blood-to-brain
transfer constants from multiple-time uptake data. Generali
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in fact it was often described as “pleasurable”.

In all patients, T2 MR images showed a region of high
signal intensity around the tips of the catheters. This response
30
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mo st evident following the dose escalation of r-metHuGDNF.
Uncertainty as to the relevance of these changes, led to a
reduction of r-metHuGDNF delivery back to 14.4 ug/puta
men/ day for all patients between 3 and 6 months that resulted
in a substantial reduction of the high signal.

Ef?cacy of r-metHuGDNF Infusion

Improvement in patients’ parkinsonian symptoms and

Occipital counts from the same time frames were used to

signs were evident within 3 months of commencing the infu
40

sion and continued to improve throughout the study. Patient
diaries revealed that periods of severe immobility, one of the

stereotaxic MNI space. The transformation matrix was then

applied to the Ki images. After normalization a gaussian ?lter
(6x6><6 mm) was applied. Mean voxel values of the normal
ized Ki images were compared throughout the midbrain and
basal ganglia at baseline, 6, and 12 months postoperatively
using a paired Student’s t-test in SPM99 after application of

varied between patients, and even between the two hemi

spheres in bilaterally implanted cases. The signal change was

zations. J. Cereb. Blood Flow Metab, 5: 584-590 (1985)).

generate the tissue reference input function. Integrated
images (time frames 25.5-94.5) were used to identify the
parameters required to transform the Ki images into standard

after the dose change discussed below that was instituted after
the appearance of a high-density signal on MRI (end of month
3). The Lherrnitte’s events were mild, intermittent, non-dis
tressing; and mo st frequently occurred at the higher dose; and
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cardinal features of PD that occupied approximately 20% of
the waking day prior to surgery, were eliminated completely
by 6 months of r-metHuGDNF infusion. At 24-months dys
kinesias were reduced signi?cantly by 73% in duration
(p<0.05) and were all reported as mild in nature (Table 4). We
observed mild dyskinesias in the practically de?ned off state

a mask to eliminate cortical signals and so reduce the number

in P4, who additionally reported short-lived infrequent early

of statistical comparisons.Any regional increases in 1 8F-dopa

morning occurrences. These changes were not due to

uptake could subsequently be de?ned as a volume of interest
and the mean Ki values for those volumes extracted using the

appropriate SPM tool (Brett, M., et al., Region of interest
analysis using an SPM toolbox, Neurolmage, 16 (2002)).
The integrated images were subsequently co-registered to
each patient’s MRI scan for region of interest (ROI) analysis.
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medication on demand due to frequent periods of akinesia at
the inset of the study, and needed to reduce his medication as
55

All MRIs had been previously reformatted in the AC-PC
plane. The subsequent transformation matrix was then
applied to individual Ki images in order to transform them
into the individual MRI space. Regions of interest (ROIs)
were traced on the MRI and included the head of the caudate
and the dorsal putamen which was divided into anterior and

his symptoms improved. Patient P5 had increased sensitivity
to L-dopa after GDNF infusion and also needed to reduce his

dosage. The other 3 patients needed slight increases in their
L-dopa equivalents intake. At 24 months, the mean daily dose
of L-dopa equivalents was reduced by 26% (based on a for
60

mula as designated by Pahwa, et. al. (Pahwa, R., et al., High
frequency stimulation of the globus pallidus for the treatment
ofParkinson’s disease, Neurology, 49: 249-253 (1997)).
The most widely used and validated scale for assessing
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Rating Scale (UPDRS). In all patients, the rate of symptom

posterior halves. The position of the catheter tip was also
calculated relative to the AC-PC line and an oval region of

interest (6 mm><12 mm) centred at the tip location in the axial
plane. The ROI was then copied onto 2 planes either side of
the slice containing the calculated tip location, creating a 12
mm><6 mm><5 mm (0.36 cc) volume of interest centered on the

increases in medication. The study protocol aimed to main
tain medication unchanged throughout the ?rst year of
r-metHuGDNF treatment. However, P3 had been taking

functional changes in PD is the Uni?ed Parkinson’s Disease
atic improvement was maximal in the ?rst 3 months of GDNF
infusion and, thereafter, there was slower but sustained

